We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
McKesson (MCK) Stock Moves -1.2%: What You Should Know
Read MoreHide Full Article
McKesson (MCK - Free Report) closed the most recent trading day at $346.68, moving -1.2% from the previous trading session. This change was narrower than the S&P 500's 2.8% loss on the day. Elsewhere, the Dow lost 2.11%, while the tech-heavy Nasdaq lost 0.1%.
Coming into today, shares of the prescription drug distributor had lost 5.21% in the past month. In that same time, the Medical sector lost 1.18%, while the S&P 500 lost 4.08%.
Wall Street will be looking for positivity from McKesson as it approaches its next earnings report date. In that report, analysts expect McKesson to post earnings of $6.13 per share. This would mark a year-over-year decline of 0.33%. Meanwhile, our latest consensus estimate is calling for revenue of $69.66 billion, up 4.64% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $24.42 per share and revenue of $276.88 billion. These totals would mark changes of +3.08% and +4.89%, respectively, from last year.
Any recent changes to analyst estimates for McKesson should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. McKesson currently has a Zacks Rank of #2 (Buy).
Looking at its valuation, McKesson is holding a Forward P/E ratio of 14.37. For comparison, its industry has an average Forward P/E of 16.59, which means McKesson is trading at a discount to the group.
Meanwhile, MCK's PEG ratio is currently 1.43. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Dental Supplies industry currently had an average PEG ratio of 1.88 as of yesterday's close.
The Medical - Dental Supplies industry is part of the Medical sector. This group has a Zacks Industry Rank of 169, putting it in the bottom 33% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
McKesson (MCK) Stock Moves -1.2%: What You Should Know
McKesson (MCK - Free Report) closed the most recent trading day at $346.68, moving -1.2% from the previous trading session. This change was narrower than the S&P 500's 2.8% loss on the day. Elsewhere, the Dow lost 2.11%, while the tech-heavy Nasdaq lost 0.1%.
Coming into today, shares of the prescription drug distributor had lost 5.21% in the past month. In that same time, the Medical sector lost 1.18%, while the S&P 500 lost 4.08%.
Wall Street will be looking for positivity from McKesson as it approaches its next earnings report date. In that report, analysts expect McKesson to post earnings of $6.13 per share. This would mark a year-over-year decline of 0.33%. Meanwhile, our latest consensus estimate is calling for revenue of $69.66 billion, up 4.64% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $24.42 per share and revenue of $276.88 billion. These totals would mark changes of +3.08% and +4.89%, respectively, from last year.
Any recent changes to analyst estimates for McKesson should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. McKesson currently has a Zacks Rank of #2 (Buy).
Looking at its valuation, McKesson is holding a Forward P/E ratio of 14.37. For comparison, its industry has an average Forward P/E of 16.59, which means McKesson is trading at a discount to the group.
Meanwhile, MCK's PEG ratio is currently 1.43. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Dental Supplies industry currently had an average PEG ratio of 1.88 as of yesterday's close.
The Medical - Dental Supplies industry is part of the Medical sector. This group has a Zacks Industry Rank of 169, putting it in the bottom 33% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.